Login to Your Account

It's Deja Vu All Over Again for Adventrx's Exelbine

By Mari Serebrov

Thursday, August 11, 2011
Adventrx Pharmaceuticals Inc. finds itself once again requesting a meeting with the FDA so it can make its case for lung cancer drug Exelbine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription